Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...

CPC review of 5,000 sales finds Compass at 29.7% to 39.5% share in five metros, raising double-ending and private listing ...

Digital Science announces the launch of Compass by Dimensions, a dedicated publication impact tracking solution designed for ...

Compass Pathways may be the first to benefit from an accelerated approval process.

Investing.com - Stifel reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ:CMPX) shares, well above the current stock price of $5.10. The biotech company has delivered a ...

A Compass sales manager argues MLS exposure is valuable but not always optimal, and says pre market sequencing can reduce price adjustment risk. He cites Compass data that 93% of listings involve ...

Investing.com - Compass Point reiterated a Buy rating and $45 price target on Applied Digital (NASDAQ:APLD) following the company’s fiscal third-quarter results. The stock currently trades at $27.79, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min San Francisco's housing market ...

A recent analysis of home sales in top Compass markets shows just how much the brokerage has increased its market share since ...

Midwest Real Estate Data is expanding its MLS nationwide, giving any licensed real estate agent access to its platform and PLN.